"Nanosomes, when they land on the cell, become part of the cell and can release its content right into the cytoplasm and therefore have a high efficacy in terms of transfection."
Trevor Castor, president and CEO, Aphios Corp., which is tackling the ultimate treatment, a cure for HIV infection, using its critical fluid nanosome technology to deliver small interfering RNA

"A disorderly Brexit has the potential to have a very negative impact on patient health across Europe. Negotiators from both the EU and the U.K. have a responsibility to do everything they can to avoid this risk."
Nicola Bedlington, secretary general of the European Patients' Forum, an umbrella body representing 74 patients' groups

"We've previously shown we can deliver viral genes to tumors, so it should be possible to show we can deliver therapeutic genes. The next stage is to show there is a therapeutic effect."
John Beadle, CEO, Psioxus Therapeutics Ltd., which has received approval for a phase I trial of NG-348, the first of its gene therapy for tumor products, triggering a $15 million milestone from partner Bristol-Myers Squibb Co.